Trevi Therapeutics Announces Executive Team Changes and Haduvio Progress
Company Announcements

Trevi Therapeutics Announces Executive Team Changes and Haduvio Progress

The latest update is out from Trevi Therapeutics ( (TRVI) ).

Trevi Therapeutics, a biopharmaceutical company focused on chronic cough treatments, has announced key executive changes with James Cassella joining as Chief Development Officer and David Clark stepping down as Chief Medical Officer but continuing as a consultant. The company’s investigational therapy, Haduvio, aims to address unmet medical needs in chronic cough conditions and is advancing towards pivotal development and potential regulatory submission. Cassella’s extensive experience in CNS drug development is expected to significantly contribute to Haduvio’s progress.

For a thorough assessment of TRVI stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyStifel says Trevi’s RIVER enrollment completion puts data release in Q1 2025
TheFlyStifel says Trevi’s RIVER enrollment completion puts data release in Q1 2025
TheFlyTrevi Therapeutics completes enrollment for Phase 2a RIVER trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App